2 completed, 2 unknown. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Unknown 2 |
| Phase 3 | 1 | Completed 1 |
Follow Fasenra: new trials by email Literature Review of Fasenra trials Research Report on Fasenra
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Benralizumab Initiated During Severe Asthma Attack Benralizumab 30 MG/ML [Fasenra], Placebos - Asthma Attack, Asthma | Phase 2 | Unknown | Singapore General Hospital | 128 | 2021-06-02 | 2021-07-23 |
| Acute Exacerbations Treated With BenRAlizumab (The ABRA Study) Benralizumab, Prednisolone - Asthma, COPD | Phase 2 | Unknown | University of Oxford | 158 | 2021-03-29 | 2024-01-23 |
| Benralizumab for Eosinophilic Gastritis (BEGS) Benralizumab, Placebo - Eosinophilic Gastritis or Gastroenteritis | Phase 2 / Phase 3 | Completed | Children's Hospital Medical Center, Cincinnati | 26 | 2018-04-23 | 2022-02-03 |
| Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis Benralizumab, Placebo - Chronic Rhinosinusitis (Diagnosis), Nasal Polyps | Phase 2 | Completed | Johns Hopkins University | 33 | 2017-07-01 | 2021-02-11 |
Asthma (2) · Disease (1) · Eosinophilia (1) · Eosinophilic enteropathy (1) · Gastroenteritis (1) · Nasal Polyps (1) · Pulmonary Disease, Chronic Obstructive (1)
Children's Hospital Medical Center, Cincinnati (1) · Johns Hopkins University (1) · Singapore General Hospital (1) · University of Oxford (1)
United States (2) · Singapore (1) · United Kingdom (1)
Jody Tversky, MD (1) · Marc E Rothenberg, MD, PhD (1) · Mariko Koh (1) · Mona Bafadhel, PhD, MBChB (1)
PMID 25445859, PMID 27609406, PMID 27609408, PMID 31310686, PMID 33595845, PMID 34110505, PMID 37336228, PMID 39615502
2018 (1)